The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces September 2012 Investor Conference Presentations

Wednesday, August 29, 2012

Regeneron Announces September 2012 Investor Conference Presentations09:30 EDT Wednesday, August 29, 2012TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012 Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Time on Tuesday, September 11, 2012 UBS Global Life Sciences Conference at 7:30 a.m. Eastern Time on Thursday, September 20, 2012The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications                            914-847-5126914.847.7640              manisha.narasimhan@regeneron.com peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.